Antagonists of mcp-1 function and methods of use thereof

Details Antagonists of mcp-1 function and methods of use thereof Antagonists of mcp-1 function and methods of use thereof

C - Chemistry, Metallurgy

07

D

C07D 317/54 (2006.01) A61K 31/36 (2006.01) A61P 29/00 (2006.01) C07D 209/08 (2006.01) C07D 209/14 (2006.01) C07D 235/06 (2006.01) C07D 235/14 (2006.01) C07D 249/18 (2006.01) C07D 263/14 (2006.01) C07D 263/56 (2006.01) C07D 307/79 (2006.01) C07D 307/81 (2006.01) C07D 317/68 (2006.01) C07D 405/12 (2006.01) C07D 407/12 (2006.01) C07D 409/12 (2006.01) C07D 411/12 (2006.01) C07D 413/12 (2006.01) C07D 417/12 (2006.01)

Patent

CA 2442776

The present invention relates to chemical compounds Ia, IIa and IIIa, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

L'invention porte sur des composés chimiques Ia, IIa, et IIIa, sur des compositions pharmaceutiques comprenant lesdits composés, sur les utilisations desdits composés et desdites compositions, sur les procédés de traitement faisant appel à ces composés et compositions et sur les procédés de préparation desdits composés. L'invention porte plus particulièrement sur de nouveaux composés qui sont des antagonistes de la fonction de la protéine chimioattractive monocytaire-1 (MCP-1) utilisés dans la prévention ou le traitement de maladies inflammatoires ou auto-immunes chroniques ou aiguës, notamment celles associées à l'accumulation aberrante de lymphocytes ou monocytes, dont l'arthrite, l'asthme, l'athérosclérose, la néphropathie diabétique, les inflammations des selles, la maladie de Crohn, la sclérose en plaques, la néphrite, la pancréatite, la fibrose pulmonaire, la psoriasis, la resténose, et le rejet de greffes. L'invention porte plus spécifiquement sur des compositions pharmaceutiques renfermant ces composés et sur l'utilisation de ces composés et compositions dans la prévention ou le traitement desdites maladies.

Affiliated with

Also associated with

Rating

Antagonists of mcp-1 function and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of mcp-1 function and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of mcp-1 function and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1637626